PYRIDOPYRIMIDINONE COMPOUNDS AND APPLICATIONS THEREOF
The present disclosure provides the Pyridopyrimidinone compounds having the structure represented by the general Formula (II) and applications thereof. Studies have shown that the compounds provided by the present disclosure can effectively inhibit the KRAS G12C mutation. KRAS mutation accounts for...
Gespeichert in:
Hauptverfasser: | , , , , , , , , , |
---|---|
Format: | Patent |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext bestellen |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | |
container_start_page | |
container_title | |
container_volume | |
creator | CAI, Xiong LIN, Mingsheng FAN, Fushun LIU, Bin QIAN, Changgeng HE, Qijie QING, Yuanhui LIU, Yiting WENG, Yunwo FENG, Qiao |
description | The present disclosure provides the Pyridopyrimidinone compounds having the structure represented by the general Formula (II) and applications thereof. Studies have shown that the compounds provided by the present disclosure can effectively inhibit the KRAS G12C mutation. KRAS mutation accounts for a large proportion of tumors, and currently there is no approved drug for its treatment. The compounds provided by the present disclosure have the potential to become a therapeutic medicine for malignant tumors (especially non-small cell lung cancer (NSCLC) and colorectal cancer) haboring KRAS G12C mutation, and have great application value. |
format | Patent |
fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_US2022389013A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>US2022389013A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_US2022389013A13</originalsourceid><addsrcrecordid>eNrjZDANiAzydPEHkb6eLp5-_n6uCs7-vgH-oX4uwQqOfi4KjgEBPp7OjiGe_n7BCiEerkGu_m48DKxpiTnFqbxQmptB2c01xNlDN7UgPz61uCAxOTUvtSQ-NNjIwMjI2MLSwNDY0dCYOFUA0ccpGQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>PYRIDOPYRIMIDINONE COMPOUNDS AND APPLICATIONS THEREOF</title><source>esp@cenet</source><creator>CAI, Xiong ; LIN, Mingsheng ; FAN, Fushun ; LIU, Bin ; QIAN, Changgeng ; HE, Qijie ; QING, Yuanhui ; LIU, Yiting ; WENG, Yunwo ; FENG, Qiao</creator><creatorcontrib>CAI, Xiong ; LIN, Mingsheng ; FAN, Fushun ; LIU, Bin ; QIAN, Changgeng ; HE, Qijie ; QING, Yuanhui ; LIU, Yiting ; WENG, Yunwo ; FENG, Qiao</creatorcontrib><description>The present disclosure provides the Pyridopyrimidinone compounds having the structure represented by the general Formula (II) and applications thereof. Studies have shown that the compounds provided by the present disclosure can effectively inhibit the KRAS G12C mutation. KRAS mutation accounts for a large proportion of tumors, and currently there is no approved drug for its treatment. The compounds provided by the present disclosure have the potential to become a therapeutic medicine for malignant tumors (especially non-small cell lung cancer (NSCLC) and colorectal cancer) haboring KRAS G12C mutation, and have great application value.</description><language>eng</language><subject>CHEMISTRY ; HETEROCYCLIC COMPOUNDS ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2022</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20221208&DB=EPODOC&CC=US&NR=2022389013A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,309,781,886,25568,76551</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20221208&DB=EPODOC&CC=US&NR=2022389013A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>CAI, Xiong</creatorcontrib><creatorcontrib>LIN, Mingsheng</creatorcontrib><creatorcontrib>FAN, Fushun</creatorcontrib><creatorcontrib>LIU, Bin</creatorcontrib><creatorcontrib>QIAN, Changgeng</creatorcontrib><creatorcontrib>HE, Qijie</creatorcontrib><creatorcontrib>QING, Yuanhui</creatorcontrib><creatorcontrib>LIU, Yiting</creatorcontrib><creatorcontrib>WENG, Yunwo</creatorcontrib><creatorcontrib>FENG, Qiao</creatorcontrib><title>PYRIDOPYRIMIDINONE COMPOUNDS AND APPLICATIONS THEREOF</title><description>The present disclosure provides the Pyridopyrimidinone compounds having the structure represented by the general Formula (II) and applications thereof. Studies have shown that the compounds provided by the present disclosure can effectively inhibit the KRAS G12C mutation. KRAS mutation accounts for a large proportion of tumors, and currently there is no approved drug for its treatment. The compounds provided by the present disclosure have the potential to become a therapeutic medicine for malignant tumors (especially non-small cell lung cancer (NSCLC) and colorectal cancer) haboring KRAS G12C mutation, and have great application value.</description><subject>CHEMISTRY</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2022</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZDANiAzydPEHkb6eLp5-_n6uCs7-vgH-oX4uwQqOfi4KjgEBPp7OjiGe_n7BCiEerkGu_m48DKxpiTnFqbxQmptB2c01xNlDN7UgPz61uCAxOTUvtSQ-NNjIwMjI2MLSwNDY0dCYOFUA0ccpGQ</recordid><startdate>20221208</startdate><enddate>20221208</enddate><creator>CAI, Xiong</creator><creator>LIN, Mingsheng</creator><creator>FAN, Fushun</creator><creator>LIU, Bin</creator><creator>QIAN, Changgeng</creator><creator>HE, Qijie</creator><creator>QING, Yuanhui</creator><creator>LIU, Yiting</creator><creator>WENG, Yunwo</creator><creator>FENG, Qiao</creator><scope>EVB</scope></search><sort><creationdate>20221208</creationdate><title>PYRIDOPYRIMIDINONE COMPOUNDS AND APPLICATIONS THEREOF</title><author>CAI, Xiong ; LIN, Mingsheng ; FAN, Fushun ; LIU, Bin ; QIAN, Changgeng ; HE, Qijie ; QING, Yuanhui ; LIU, Yiting ; WENG, Yunwo ; FENG, Qiao</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_US2022389013A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2022</creationdate><topic>CHEMISTRY</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>CAI, Xiong</creatorcontrib><creatorcontrib>LIN, Mingsheng</creatorcontrib><creatorcontrib>FAN, Fushun</creatorcontrib><creatorcontrib>LIU, Bin</creatorcontrib><creatorcontrib>QIAN, Changgeng</creatorcontrib><creatorcontrib>HE, Qijie</creatorcontrib><creatorcontrib>QING, Yuanhui</creatorcontrib><creatorcontrib>LIU, Yiting</creatorcontrib><creatorcontrib>WENG, Yunwo</creatorcontrib><creatorcontrib>FENG, Qiao</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>CAI, Xiong</au><au>LIN, Mingsheng</au><au>FAN, Fushun</au><au>LIU, Bin</au><au>QIAN, Changgeng</au><au>HE, Qijie</au><au>QING, Yuanhui</au><au>LIU, Yiting</au><au>WENG, Yunwo</au><au>FENG, Qiao</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>PYRIDOPYRIMIDINONE COMPOUNDS AND APPLICATIONS THEREOF</title><date>2022-12-08</date><risdate>2022</risdate><abstract>The present disclosure provides the Pyridopyrimidinone compounds having the structure represented by the general Formula (II) and applications thereof. Studies have shown that the compounds provided by the present disclosure can effectively inhibit the KRAS G12C mutation. KRAS mutation accounts for a large proportion of tumors, and currently there is no approved drug for its treatment. The compounds provided by the present disclosure have the potential to become a therapeutic medicine for malignant tumors (especially non-small cell lung cancer (NSCLC) and colorectal cancer) haboring KRAS G12C mutation, and have great application value.</abstract><oa>free_for_read</oa></addata></record> |
fulltext | fulltext_linktorsrc |
identifier | |
ispartof | |
issn | |
language | eng |
recordid | cdi_epo_espacenet_US2022389013A1 |
source | esp@cenet |
subjects | CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
title | PYRIDOPYRIMIDINONE COMPOUNDS AND APPLICATIONS THEREOF |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-17T11%3A39%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=CAI,%20Xiong&rft.date=2022-12-08&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EUS2022389013A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |